Skip to main content
Premium Trial:

Request an Annual Quote

Symyx Revenue, Income, and R&D Spending Dip in Q2

NEW YORK, July 26 - Symyx Technologies today reported a 9-percent dip in total revenue atop decreased net income and slightly trimmed R&D spending.

 

Total revenue for the period ended June 30 was $14 million compared with $15.4 million the company reported one year ago. Symyx blamed the reduction on a decrease in collaboration revenue to $9.4 million in the current second quarter from $10.6 million for the same period last year. The company said this kind of revenue represented some 67 percent of total revenue for the quarter.

 

Meantime, second-quarter revenue from products, royalties, and licenses was a combined $4.6 million for the quarter compared to $4.7 million for the same period in 2001, Symyx said.

 

The company spent $9.6 million in R&D in the current quarter, down from $10 million year over year.

 

Still, net income for the quarter fell to $684,000, or $.02 per share, compared to $1.7 million, or $.05 per share, reported in the same quarter last year.

 

Symyx said it had roughly $117.8 million in cash, cash equivalents, and short-term investments as of June 30.

 

Looking ahead, the company said it expects to post total combined annual revenues of between $65 million and $70 million, which is below the $80 million to $85 million Symyx originally expected to book by Dec. 31. The guidance is still about 10 percent above what the company brought in 2001, Symyx said.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.